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CONCLUSIONS: Cardiovascular diseases are still leading cause of death in BH, so
we suggest deeper analysis of all guidelines, programs and interventions focused to
decreasing CV mortality and making Government(s) expenditure in CV drugs more
efficient.
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OBJECTIVES: In October 2010, the Irish healthcare payer (i.e. the Health Service
Executive, HSE) introduced a €0.50c charge on all prescription items dispensed
under the General Medical Services (GMS) scheme, the largest of the community
drug schemes in Ireland covering approximately 40% of the population. We inves-
tigated whether this charge was associated with changes in drug utilisation.
METHODS: Monthly prescription dispensing was analysed from September 2009 to
September 2010 (pre-intervention period) and then from November 2010 to March
2011 (post intervention period). In addition to utilization (prescription items) and
cost information the database classifies drugs according to whether they are ge-
neric, off-patent or patent. The volume of drugs dispensed in each class was cal-
culated and trends in utilsation and expenditure from the pre intervention period
were compared with those in the post intervention period using segmented regres-
sion analysis. All analyses were performed using SAS (v9.1, SAS Institute Inc. Cary,
US). Statistical significance at p,0.05 is assumed throughout. RESULTS: No effect
was noted following the introduction of the prescription charge on prescription
items in the post intervention period. A decrease in ingredient cost was noted
however, for generics in the month post the intervention (p,0.01). A change in the
overall trend for ingredient cost of off-patents was noted also in the post interven-
tion period (p,0.05). The intervention had no significant effect on utilization and
expenditure of patented medicines. CONCLUSIONS: The study findings suggest
that the recent introduction of a prescription charge has had no significant effect
on utilization of prescription medicines, while decreased expenditures could be
attributed to changes in the pricing mechanisms for generics and off-patents oc-
curring around this time. Further analysis is warranted to determine if the effect on
utilization is sustained over time.
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OBJECTIVES: Various studies have been performed on potentially inappropriate
medications (PIM) in the elderly. In developed countries, Beers criteria or Zhan
criteria are widely utilized. We developed a Japanese version of Beers criteria and
are using it in clinical practice. Almost no epidemiological surveys have been per-
formed on PIM in Japan. However, it is clear that dangerous prescriptions including
unnecessary and multidrug prescriptions are often written. The objective of this
study is to clarify the prevalence of PIM in elderly people 65 or older treated at
home. METHODS: The subjects were elderly people 65 or older under home care in
the Tokyo area who were prescribed drugs in routine practice. The survey was
conducted in 300 randomly sampled pharmacies. The survey forms were distrib-
uted to the pharmacists by mail. After the pharmacists entered the drug prescrip-
tion information, they returned the forms by post. RESULTS: Replies were obtained
from 130 pharmacies (recovery rate: 43.3%). The 84 patients included 30 men and 54
women with a mean age of 82. Medical conditions included hypertension (56%),
cognitive impairment (21.4%), ischemic heart disease (16.7%) and diabetes (11.9%).
Drugs prescribed based on the Japanese version of Beers criteria accounted for
52.4% and included famotidine (30%), digoxin (5%) and ticlopidine (3.3%). Drug
types included peptic ulcer drugs (48.3%), vasodilators (8.3%) and anti-Parkinson-
ism agents (6.7%). CONCLUSIONS: In the first epidemiological survey on PIM in the
elderly undergoing home care in Japan, PIM were evident in 52.4%, a high percent-
age compared data on PIM to date. Peptic ulcer drugs were the most common and
prescriptions of ticlopidine were also high when compared with other countries.
This survey had several limitations such as being limited to Tokyo and relatively
few subjects. In the future, we hope to perform a survey with greater precision in
more subjects in the future.
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BACKGROUND: The Valencian Community, with 5,000,000 inhabitants, is imple-
menting a system of pharmaceutical management to reduce costs. This system is
based on classifying patients in groups using the case mix system, Clinical Risk
Groups. An electronic tool has been developed based on www to manage patients
with chronic conditions and monitor pharmaceutical expenditure in primary
health care. GPs receive a report on the real pharmaceutical cost that is being
incurred and the optimum cost adjusted by CRG. OBJECTIVES: To evaluate the
predictive ability of the Clinical Risk Group System in predicting pharmaceutical
expenditure in the Valencian Community. METHODS: We ran a generalized linear
model to examine the predictive validity of the CRG system and report the corre-
lation between the predicted and observed expenditures. We reported mean pre-
dictive ratios across medical condition and cost-defined groups. RESULTS: The CRG
system predicted pharmaceutical expenditure with precision, excepting for groups
8 and 9 of ACRG3. A new weight adjusted model has been developed to better fit
pharmaceutical expenditure in primary health care to the real situation in
Valencia. CONCLUSIONS: In order to use the CRG system to estimate pharmaceu-
tical expenditure in primary health care, the groups of greater clinical risk must be
weight adjusted, as the pharmaceutical consumption of these groups is hospital-
based.
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OBJECTIVES: The principle of equitable treatment establishes that everyone has
the right of access to preventive health care and the right to benefit from medical
treatment. Variations in market uptake of orphan drugs have important implica-
tions with respect to access to care and inequality of treatment. Therefore, the aim
of this descriptive study is to examine the uptake of orphan drugs in Europe.
METHODS: We analyzed both the sales and volume uptake from 17 orphan drugs in
24 European countries from 2001 until the beginning of 2010 using the IMS Health
database. Countries were clustered based on differences in demographics, gross
domestic product (GDP) and patent protection law. RESULTS: This study shows
that there is a difference in the uptake of orphan drugs across European countries.
Not only does the number of orphan drugs launched differ, the sales on orphan
drugs and the share of orphan drugs sales on total market sales also vary strongly.
Additionally, the volume uptake and the share spent on orphan drugs during the
first year after the launch are highest in countries with high GDP and strong patent
laws. CONCLUSIONS: The uptake of orphan drugs could be promoted through a
variety of mechanisms such as the harmonization of European patent laws, the
implementation of conditional reimbursement mechanisms, and the introduction
of non-binding EU scientific assessment reports on the clinical added value of
orphan drugs.
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OBJECTIVES: Most countries including Malaysia are facing escalating healthcare
expenditures. The purpose of this study was to evaluate general public’s expendi-
ture on health products. METHODS: A cross-sectional study using convenience
sampling technique was used in this study. 800 questionnaires were distributed to
the general public in the state of Penang Malaysia. All data were analysed using
descriptive and appropriate inferential statistics at alpha value of 0.05. RESULTS: A
total of 56.73% of total 704 respondents felt that branded medicines were expensive
or moderate, while 56.53% of them felt that the cost of generic medicines were
moderate. In terms of private market, the costs of health products sold in commu-
nity pharmacies were perceived to be cheaper as compared to private clinics and
private hospitals. The mean of monthly expenditure per household on moderns
medicines, vitamins and non-herbal health supplements, and herbal products
were RM 171.80, RM 125.41 and RM 61.03, respectively (1 USD 5 RM3.30). Respon-
dents’ age, gender, race and income were found significantly affecting on patients’
responses. CONCLUSIONS: This study has highlighted the need to control the med-
icines prices in the private market especially in private clinics and private hospi-
tals. There is a need to promote generic products and to educate patients about the
evidence based medicine since a good proportion of their income is monthly spent
on herbal products.
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OBJECTIVES: To assess the impact of pharmaceutical part of the health care reform
in Croatia as compared with trends observed in EU countries. METHODS: Detailed
historical pharmaceutical expenditure was analysed using MIDAS, an IMS Health
proprietary database, as well as a variety of other published secondary data
sources. Croatian trends have been compared with those of a number of bench-
mark countries, categorised either as Peer Countries (Slovakia, Czech, Hungary)
and Aspirational Countries known to have systems that have been ensuring excel-
lent health care outcomes (France, The Netherlands, Austria). RESULTS: Although
total health expenditure in Croatia, as percentage of GDP is at EU level (7.8%), total
pharmaceutical spend per capita is very low, 128€, with more than 80% coming
from public funding. Pharmaceutical expenditure is not driving the overall health
cost growth; in fact, pharmaceutical spend as a % of total health expenditure has
been declining since 2003. The complex set of cost containment measures, includ-
ing limitation of GP’s prescriptions, imposed by Croatian Health Insurance Institute
is the likely cause of this trend. The most relevant finding of this study is that
Croatia has been historically very low in drug use in terms of ‘volume per capita’
compared to benchmark countries. In 2010 Croatian patients consumed approx.
20-25% less prescription medicines per capita than the average of peer and aspira-
tional countries. CONCLUSIONS: If the observed trends are allowed to continue, it
will be difficult for Croatia to keep pace with its peers in providing adequate phar-
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